FindTrial
Sign In

Glioblastoma and Individualized Therapies

Retrospective Analysis of Glioblastoma Patients With Immune Therapies

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT05356312
Enrollment
Unknown
Registered
2022-05-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma, Malignant

Brief summary

The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.

Interventions

BIOLOGICALVaccination

Personalized neoantigen vaccination

Sponsors

Zentrum fur Humangenetik Tuebingen
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL

Inclusion criteria

* malignant glioma, IDH WT

Exclusion criteria

* na

Countries

Germany

Contacts

Primary ContactSaskia Biskup, Dr. Dr.
Saskia.Biskup@humangenetik-tuebingen.de+49 (0)7071 565 44 00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026